EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endocrine and metabolic late effects in childhood cancer survivors in Germany: the VersKiK study

Pietro Trocchi iD, Enno Swart, Ekaterina Aleshchenko, Hiltrud Merzenich, Cecile Ronckers, Katja Baust, Gabriele Calaminus iD, Thorsten Langer iD, Peter Ihle, Jutta Küpper-Nybelen, Christian Lüpkes, Patrik Dröge und 7 weitere

European Journal of Endocrinology · 2026

DOI: 10.1093/ejendo/lvag010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, 2026. Verfasst von Pietro Trocchi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University, 39120 Magdeburg, Germany. Hauptthemen laut MEDLINE: Cancer Survivors, Endocrine System Diseases, Metabolic Diseases, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Fund of the Federal Joint Committee in Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Endocrine and metabolic diseases are known to be common late effects in childhood cancer survivors (CCS). We assessed the prevalence of these diseases in a large German CCS cohort, and a matched comparison population, using health claims data.

Design

The cohort study was based on record linkage between the nationwide German Childhood Cancer Registry and claims data from 13 major German statutory health insurances.

Methods

The monitored insurance period covered the years 2017-2021. We assessed the frequencies of endocrine and metabolic diseases among 11 863 five-year CCS, diagnosed 1991-2021, with continuous insurance coverage and a matched comparison group of 35 589 insured persons without a history of childhood cancer. We present prevalence and prevalence ratios (PR) with corresponding 95% confidence intervals (95% CI).

Results

At least one endocrine or metabolic disease was recorded in 31.3% of survivors (n = 3716) and in 16.4% of the comparison group (n = 5819, PR = 1.9; 95% CI: 1.8-2.0). The frequency of diseases was higher among females than among males in both groups. The PR was 2.4 (95% CI: 2.3-2.5) for males and 1.6 (95% CI: 1.5-1.7) for females. The frequency of at least one disease increased with increasing attained age. The disease with the highest frequency among CCS was hypothyroidism (15.85%), and the highest PR was estimated for patients with primary thyroid cancer (43.5; 95% CI: 24.2-78.1).

Conclusions

Our study highlights the increased vulnerability of CCS to endocrine and metabolic diseases compared to the general population and underscores the need for risk-adapted surveillance during the whole survivorship trajectory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer SurvivorsEndocrine System DiseasesMetabolic DiseasesNeoplasmsHumansMaleFemaleGermanyChildAdolescentAdultCohort StudiesRegistriesChild, PreschoolPrevalenceYoung AdultInfant

Stichwörter der Autor:innen

cancer registrycancer survivorshipchildhood cancerclaims datafollow-up carelate effects

Autor:innen und Institutionen

  • Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University, 39120 Magdeburg, Germany.
  • German Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics, University Medical Centre of Johannes Gutenberg University Mainz, 55101 Mai…
  • Division of CAYA Cancer Survivorship Research, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Department of Paediatric Haematology and Oncology, University Hospital Bonn, 53127 Bonn, Germany.
  • Department of Paediatric Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, 23538 Lübeck, Germany.
  • PMV Research Group at the Department of Child and Adolescent Psychiatry, Psychotherapy, and Psychosomatics, University Hospital of Cologne and University of Cologne, Faculty of Medicine, 50931 Cologne, Germany.

ORCID-Profile: Pietro Trocchi, Gabriele Calaminus, Thorsten Langer, Thomas Ruhnke, Claudia Spix, Christian Apfelbacher

Förderung

  • Innovation Fund of the Federal Joint Committee in Germany

Zitieren

APA

Trocchi, P., Swart, E., Aleshchenko, E., Merzenich, H., Ronckers, C., Baust, K., Calaminus, G., Langer, T., Ihle, P., Küpper-Nybelen, J., Lüpkes, C., Dröge, P., Ruhnke, T., Horenkamp-Sonntag, D., Marschall, U., Klein, M., Spix, C., Apfelbacher, C., & Gebauer, J. (2026). Endocrine and metabolic late effects in childhood cancer survivors in Germany: the VersKiK study. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvag010

Vancouver

Trocchi P, Swart E, Aleshchenko E, Merzenich H, Ronckers C, Baust K, et al. Endocrine and metabolic late effects in childhood cancer survivors in Germany: the VersKiK study. European Journal of Endocrinology. 2026. doi:10.1093/ejendo/lvag010

BibTeX
@article{Trocchi2026,
  author = {Trocchi, Pietro and Swart, Enno and Aleshchenko, Ekaterina and Merzenich, Hiltrud and Ronckers, Cecile and Baust, Katja and Calaminus, Gabriele and Langer, Thorsten and Ihle, Peter and Küpper-Nybelen, Jutta and Lüpkes, Christian and Dröge, Patrik and Ruhnke, Thomas and Horenkamp-Sonntag, Dirk and Marschall, Ursula and Klein, Melanie and Spix, Claudia and Apfelbacher, Christian and Gebauer, Judith},
  title = {Endocrine and metabolic late effects in childhood cancer survivors in Germany: the VersKiK study},
  journal = {European Journal of Endocrinology},
  year = {2026},
  doi = {10.1093/ejendo/lvag010}
}
Kostenlos starten →